Project Grant R01AR087686
Award Date 8/1/26
Completion Date 5/31/31
Dollars Obligated $429K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Dayton, OH 45435, USA
Similar Awards
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded New York University $148,062 on September 30, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The funded research investigates the mechanism by which epithelial stem and progenitor cells encode inflammatory memory in psoriasis and other remitting-relapsing inflammatory disorders. The study tests whether homeostatic and inflammatory transcription factors dynamically...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded University of California Irvine $249,000 on February 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) for Project Grant R00AR083536. The award funds research to decode the repair and immunomodulatory functions of lymphatic vessels in wound healing. The research aims to delineate mechanisms and consequences of lymphatic vessel remodeling during skin repair and to...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of California, San Diego $559,827 on September 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms regulating inflammatory responses in epidermal keratinocytes. The research will characterize the role of the ZNF750 protein complex and its associated factors (KDM1A/LSD1, SETDB1, TRIM28/KAP1, and HNRNPU) in mediating...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Southwestern Medical Center $578,211 on August 7, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund investigator-initiated research defining how epidermal NADPH depletion and redox imbalance disrupt skin barrier function and drive systemic metabolic effects. The project addresses the physiological roles of NAD kinase (NADK) and NADPH...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) awarded The Washington University $258,070 on September 26, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to fund a five-year physician-scientist training and mentored research program examining the role of centrosomal protein CEP43 in epidermal homeostasis and cutaneous inflammatory diseases. The research project investigates mechanisms by which loss of CEP43 leads...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $1.696 million to Poly Orth International on September 15, 2025, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The award funds translational pre-clinical research and development of a 3D-printed skin and bone integrated pylon (SBIP-3D) for direct skeletal attachment of limb prostheses. The technology, developed by Poly Orth International, integrates with both residual bone...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Washington University $916,572 on July 6, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate immune mechanisms driving psoriasis and related inflammatory skin conditions. The research focuses on CD5+ dendritic cells, a subset that accumulates in psoriatic lesions and drives autoimmune T cell activation, disrupting skin immune tolerance. The project will define...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded $676,210 to The Washington University on August 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The recipient will conduct research into DNMT3A as an epigenetic transcriptional therapeutic target in femoroacetabular impingement (FAI) progression to osteoarthritis. FAI is a pre-arthritic hip condition affecting individuals aged 20 to 40; standard surgical treatment...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded Northwestern University $524,335 on June 5, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846) to investigate the molecular mechanisms governing how the PBAF chromatin remodeling complex switches between repressing and activating epidermal differentiation genes. The project, titled "Dynamic Regulation of Epidermal Differentiation Genes by Cell-State-Specific PBAF...
- The National Institute of Arthritis and Musculoskeletal and Skin Diseases awarded the University of Texas Health Science Center at Houston $156,000 on July 1, 2026, under the Arthritis, Musculoskeletal and Skin Diseases Research program (CFDA 93.846). The project investigates pulmonary arterial hypertension susceptibility in systemic sclerosis patients carrying the DNASE1L3 R206C genetic variant. Aim 1 will assess the impact of chronic DNASE1L3 deficiency on the pulmonary vasculature in mice...